Defining molecular contributions of LINE-1 retrotransposons to AD / ADRD

定义 LINE-1 逆转录转座子对 AD / ADRD 的分子贡献

基本信息

  • 批准号:
    10701914
  • 负责人:
  • 金额:
    $ 74.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-15 至 2027-05-31
  • 项目状态:
    未结题

项目摘要

Project Summary: Alzheimer's Disease (AD) and AD-related dementias (ADRDs; e.g. Frontotemporal Dementia, Lewy Body Dementia, etc.) are crippling neurodegenerative disorders. The onset of these diseases is strongly correlated with aging. Cures for AD and ADRDs remain elusive; Alzheimer's has become the 6th most frequent cause of death in the USA. An emerging candidate contributor to Alzheimer's and ADRD is the L1 retrotransposon, which becomes dysregulated during aging and correlates with Alzheimer's / ADRD onset. One hypothetical mechanism by which L1 may contribute to Alzheimer's / ADRD is through its exacerbation of cellular senescence. Senescence is a phenomenon by which normal cells stop dividing; these cells accumulate with advancing age and are found at the locations of dysfunction in age-related diseases. In mice, senescent cells have been shown to shorten life and actively drive age-related neurodegeneration; preventing senescent cell accumulation decreases tau-dependent degeneration and cognitive decline. AD patients exhibit increased indicators of cellular senescence. It is increasingly clear that senescent cells are not inert, but instead drive tissue deterioration via the senescence-associated secretory phenotype - secreting a variety of growth factors and pro- inflammatory cytokines. L1 retrotransposons have recently been shown to drive progression of the senescence- associated secretory phenotype, and thus, L1 is an important agent of cellular senescence. L1 activation is also associated with AD-related Tau pathologies. The L1 encoded ORF2p enzyme (endonuclease and reverse transcriptase) is often flagged as a source of pathological cellular insults, e.g. via new, mutagenic L1 insertions and contributions to chromosomal instability. However, the effects of L1 expression extend beyond DNA damage. Numerous mechanisms may be at play, including the titration of normally homeostatic host factors away from their physiologic functions and into L1 ribonucleoprotein granules, as well as the production of immunity-and-inflammation-triggering cytoplasmic L1 DNA:RNA hybrids; indeed, the latter is now understood to be a key component of L1’s role in cellular senescence. Moreover, L1 also mobilizes Alu and other non- autonomous retrotransposons. Objectives: In Aim 1, we will use targeted mass spectrometry to profile L1 ORF1 protein expression in the cerebrospinal fluid (CSF) and post-mortem brain tissues of patients exhibiting AD/ADRD and cognitive decline, as well as in senescent cells and neuronal iPSCs; in Aim 2 (in vitro cell culture) and Aim 3 (clinical samples) we will profile L1-associated protein-protein and protein-RNA interactions in the same biological samples as Aim 1; and in Aim 4 we will take a candidate-based approach using molecular genetics to dissect the mechanisms of action of L1 in senescent cells.
项目摘要:阿尔茨海默病(AD)和与AD相关的痴呆(ADRDS;例如 痴呆症、路易体痴呆症等)是严重的神经退行性疾病。这些疾病的发病 与衰老密切相关。AD和ADRD的治疗仍然难以捉摸;阿尔茨海默氏症已成为第六大 在美国常见的死因。阿尔茨海默病和ADRD的一个新的候选贡献者是L1 逆转座子,它在衰老过程中变得失调,与阿尔茨海默氏症/ADRD的发病相关。一 L1可能导致阿尔茨海默病/ADRD的假设机制是通过它的细胞恶化 衰老。衰老是一种正常细胞停止分裂的现象;这些细胞随着 随着年龄的增长,在与年龄相关的疾病的功能障碍部位被发现。在小鼠中,衰老的细胞 已被证明可以缩短寿命,并积极推动与年龄相关的神经退化;防止细胞衰老 积累可以减少依赖tau的退化和认知能力下降。AD患者表现出增加 细胞衰老的指标。越来越清楚的是,衰老的细胞不是惰性的,而是驱动组织 通过衰老相关的分泌表型而恶化--分泌多种生长因子和促进素 炎性细胞因子。L1反转录转座子最近被证明推动衰老的进展- 相关的分泌表型,因此,L1是细胞衰老的重要因素。L1激活也是 与AD相关的Tau病理有关。L1编码的ORF2p酶(内切酶和反向 转录酶)通常被标记为病理性细胞侮辱的来源,例如通过新的、诱变的L1插入 以及对染色体不稳定的贡献。然而,L1表达的影响超越了DNA 损坏。许多机制可能在起作用,包括滴定正常体内平衡的宿主因子。 远离它们的生理功能,进入L1核糖核蛋白颗粒,以及产生 免疫和炎症触发细胞质L1DNA:RNA杂交体;事实上,后者现在被理解为 是L1‘S在细胞衰老中作用的关键成分。此外,L1还动员Alu和其他非 自主反转录转座子。 目的:在目标1中,我们将使用靶向质谱学来分析L1 ORF1蛋白在 AD/ADRD和认知功能减退患者的脑脊液(CSF)和死后脑组织, 在Aim 2(体外细胞培养)和Aim 3(临床样本)中,我们 将在与目标1相同的生物样本中描述L1相关的蛋白质-蛋白质和蛋白质-RNA相互作用; 在目标4中,我们将采用基于候选对象的方法,使用分子遗传学来剖析 L1在衰老细胞中的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John Paul LaCava其他文献

John Paul LaCava的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John Paul LaCava', 18)}}的其他基金

Defining molecular contributions of LINE-1 retrotransposons to AD / ADRD
定义 LINE-1 逆转录转座子对 AD / ADRD 的分子贡献
  • 批准号:
    10518515
  • 财政年份:
    2022
  • 资助金额:
    $ 74.62万
  • 项目类别:
An integrated pipeline for next-generation protein interactomics
下一代蛋白质相互作用组学的集成管道
  • 批准号:
    10061613
  • 财政年份:
    2017
  • 资助金额:
    $ 74.62万
  • 项目类别:
Monospecific monoclonal antibodies against human protein complexes on an interactome-wide scale.
在相互作用组范围内针对人类蛋白质复合物的单特异性单克隆抗体。
  • 批准号:
    9202440
  • 财政年份:
    2016
  • 资助金额:
    $ 74.62万
  • 项目类别:

相似海外基金

Interplay between Aging and Tubulin Posttranslational Modifications
衰老与微管蛋白翻译后修饰之间的相互作用
  • 批准号:
    24K18114
  • 财政年份:
    2024
  • 资助金额:
    $ 74.62万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The Canadian Brain Health and Cognitive Impairment in Aging Knowledge Mobilization Hub: Sharing Stories of Research
加拿大大脑健康和老龄化认知障碍知识动员中心:分享研究故事
  • 批准号:
    498288
  • 财政年份:
    2024
  • 资助金额:
    $ 74.62万
  • 项目类别:
    Operating Grants
EMNANDI: Advanced Characterisation and Aging of Compostable Bioplastics for Automotive Applications
EMNANDI:汽车应用可堆肥生物塑料的高级表征和老化
  • 批准号:
    10089306
  • 财政年份:
    2024
  • 资助金额:
    $ 74.62万
  • 项目类别:
    Collaborative R&D
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
  • 批准号:
    498310
  • 财政年份:
    2024
  • 资助金额:
    $ 74.62万
  • 项目类别:
    Operating Grants
関節リウマチ患者のSuccessful Agingに向けたフレイル予防対策の構築
类风湿性关节炎患者成功老龄化的衰弱预防措施的建立
  • 批准号:
    23K20339
  • 财政年份:
    2024
  • 资助金额:
    $ 74.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Life course pathways in healthy aging and wellbeing
健康老龄化和福祉的生命历程路径
  • 批准号:
    2740736
  • 财政年份:
    2024
  • 资助金额:
    $ 74.62万
  • 项目类别:
    Studentship
I-Corps: Aging in Place with Artificial Intelligence-Powered Augmented Reality
I-Corps:利用人工智能驱动的增强现实实现原地老龄化
  • 批准号:
    2406592
  • 财政年份:
    2024
  • 资助金额:
    $ 74.62万
  • 项目类别:
    Standard Grant
NSF PRFB FY 2023: Connecting physiological and cellular aging to individual quality in a long-lived free-living mammal.
NSF PRFB 2023 财年:将生理和细胞衰老与长寿自由生活哺乳动物的个体质量联系起来。
  • 批准号:
    2305890
  • 财政年份:
    2024
  • 资助金额:
    $ 74.62万
  • 项目类别:
    Fellowship Award
虚弱高齢者のSuccessful Agingを支える地域課題分析指標と手法の確立
建立区域问题分析指标和方法,支持体弱老年人成功老龄化
  • 批准号:
    23K20355
  • 财政年份:
    2024
  • 资助金额:
    $ 74.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
「ケア期間」に着目したbiological aging指標の開発
开发聚焦“护理期”的生物衰老指数
  • 批准号:
    23K24782
  • 财政年份:
    2024
  • 资助金额:
    $ 74.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了